safety and anti-tumor activity of bay 2927088 in patients with her2-mutant nsclc
Published 2 months ago • 102 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
4:24
zenith20-4: efficacy & safety of poziotinib in treatment-naïve nsclc with her2 exon 20 mutations
-
4:37
neratinib-based combination therapy in her2-mutant lung cancer
-
3:27
anti-tumour activity of tak-788 in nsclc patients with egfr exon 20 insertions
-
1:12
dr. yorio on t-dm1 in her2-mutant lung cancer treatment
-
36:45
decoding her2 in nsclc: advances in biomarker testing and targeted therapies
-
3:49
zenith20: poziotinib in egfr and her2 exon 20 mutant nsclc
-
2:52
updated overall efficacy and safety of selpercatinib in patients with ret fusion nsclc
-
58:27
addressing key targets in advanced nsclc: her2-, her3-, and trop2-targeted therapies
-
1:58
zenith20: poziotinib efficacy and safety in nsclc
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
1:26
the challenge of treatment resistance in patients with advanced egfr-mutated nsclc
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
2:51
zenith20-5: poziotinib for egfr/her2 exon 20 mutant nsclc
-
4:08
targeted therapies in lung cancer
-
58:30
the potential of her2-, her3-, and trop2-targeted therapies to address unmet needs in advanced nsclc
-
6:31
gracecast - treatment options for patients with advanced nsclc and a her2- erbb2 mutation
-
18:41
extreme rare mutations in lung cancer (ros1, trk, her2): treatment opportunities
-
1:59
phase i a study evaluating gdc-6036 monotherapy in patients with nsclc with kras g12c mutation